Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
80 hedge funds and large institutions have $41M invested in Osiris Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 13 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 81 → 80 (-1)
59% less capital invested
Capital invested by funds: $100M → $41M (-$59M)
71% less call options, than puts
Call options by funds: $380K | Put options by funds: $1.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$546K |
| 2 |
D.E. Shaw & Co
New York
|
+$541K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$404K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$258K |
| 5 |
Morgan Stanley
New York
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$23.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.14M |
| 3 |
SIM
Spark Investment Management
New York
|
-$651K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$563K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$455K |
OSIR Hedge Fund Activity: Q1 2016 in Review
80 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2016, worth a combined $41M — down 59% from $100M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OSIR and 12 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 29 added.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $546K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $23.3M sold.
- 80 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2016, down from 81 in Q4 2015.
- Funds reported $41M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2016, down 59% quarter-over-quarter.
- 12 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2016 and 13 closed out, a net change of -1 holder.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2016 was Two Sigma Investments, an estimated $546K added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2016 was Consonance Capital Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q1 2016.